Professional Documents
Culture Documents
3 - Pharmacodynamics
3 - Pharmacodynamics
Lecture № 3
Module «Pharmacology»
23.01.2024 1
Pharmacodynamics
investigation of processes in the body due to the influence of
pharmaceutical substances
23.01.2024 2
Influence of PS is
found on:
Molecular;
Cellular;
Organ;
Systemic;
Whole body
levels.
23.01.2024 3
Targets for PS
Biological structure on cellular and molecular levels PS interacts
with is termed «target» (emetic center, heart)
«TARGETS»
FOR PHARMACEUTCIAL SUBSTANCES
1. Biomembrances and ionic channels
2. Receptors (outside and inside cells)
3. Enzyme systems
4. Intracellular metabolites
5. Intercellular substances
6. Infectious and parasitic agents
7. Toxins and venoms
23.01.2024 4
Targets for PS
Biological structure on molecular level PS interacts with is
termed «receptor» (pharmacological receptor)
Receptors – functionally active macromolecules (proteins,
lipoproteins, nucleoproteins, glycoproteins) or their fragments :
regulating proteins; enzymes; carrier proteins; structural
proteins
23.01.2024 7
Quantitative characteristics of drug-receptor interaction
The higher Kd , the lower affinity; the lower Kd, the higher affinity.
23.01.2024 8
Quantitative characteristics of drug-receptor interaction
23.01.2024 10
Characteristics of pharmaceutical molecules
Origin:
1. Analogues of endogenous compounds (hormones, enzymes);
2. Xenobiotics (Greek «xenos» – alien).
Sizes:
From very tiny (Li, MW=7) up to enormous (Alteplase, MW=59 050)
The major part: from 100 to 1000 Da
100 – lowest MW that can provide selectivity of binding processes;
1000 – largest size (upper limit) that can provide movement of PS throughout
the body
Shape:
Provide physical interaction with receptor
The best option – shape of PS is complementary to receptor’s shape
23.01.2024 11
Chirality phenomenon. Enantioselectivity of PS
About 50-50% of PS are chiral molecules i.e. they are enantiomer pair.
Racemic mixture (racemate) – mixture of two compounds,
which structural formulas correlate as a subject
and its mirror reflection
Enantioselectivity is different;
Potency and efficacy are different;
Metabolism rate is different;
Duration of action is different.
Enantioselectivity is different;
Potency and efficacy are different;
Metabolism rate is different;
Duration of action is different.
23.01.2024 14
Interaction of PS-agonist with receptor
23.01.2024 15
Interaction of PS-antagonist with receptors
23.01.2024 16
Mathematical evaluation of PS-receptor interaction
23.01.2024 17
Types of antagonism:
If antagonist occupies the same binding sites on receptors as agonist
does then they both are able to displace each other from the binding
sites. This is competitive antagonism.
PS – competitive antagonist (reversible).
23.01.2024 19
Type of antagonism:
23.01.2024 20
Type of antagonism:
23.01.2024 21
Drug – receptor interaction
23.01.2024 23
Drug – receptor interaction
23.01.2024 24
Drug – receptor interaction
23.01.2024 25
Physiological antagonism of PS effects
For example,
Glucocorticoid hormones increase blood glucose level,
whereas insulin exert physiological opposite influence,
because they affect different receptor-effector systems.
23.01.2024 26
Types of receptors
and signal transfer via plasmatic membrane
I. Intracellular proteins –
cytosol and nuclear proteins.
23.01.2024 28
Types of receptors
Examples:
Acetyl choline, GABA, glycine, aspartate, glutamate
23.01.2024 30
Types of receptors
3) G-protein coupled receptors:
System with three components: Receptor –
G-protein (GTP-binding protein) –
enzyme(s) or ion channel(s).
Gs-proteins→adenylate cyclase stimulation→
↑cAMP →(+) chronotropic effects;
Gi-proteins→ adenylate cyclase inhibition →
(-) chronotropic effects.
Gq-proteins →phospholipase С activation→
Hydrolysis of phosphatidylinositol 4,5-bisphosphate
→formation of inositol 1,4,5-trisphosphate→
Interaction with Ca-channels
sarcoplasmic reticulum→
release of Ca2+ into cytoplasma→
accelerated formation of Ca2+-calmodulin complex
→activation of kinase of myosin light chains→
phosphorylation of myosin light chains →
amplification of actin to myosin interaction
→smooth muscle contraction (vessels).
G-protein coupled receptors, structurally similar;
they make a group of serpentine receptors».
Examples: ACTH, norepinephrine, adrenaline, dophamine, 31
LH, TSH, PSH, glucagon.
Types of receptors
23.01.2024 32
Intracellular messengers (mediators): cAMP
23.01.2024 33
Intracellular messengers (mediators)
cAMP→stimulation of protein kinase (phosphate transfer from ATP to
substrate enzyme-proteins):
glycogen degradation in hepatocytes (glycogen phosphorylase);
triglyceride degradation in fat cells (lipase);
smooth muscle relaxation (phosphorylation of myosin light chain kinase).
23.01.2024 34
Intracellular messengers (mediators)
Ca2+ and phosphoinositides:
23.01.2024 35
Intracellular messengers (mediators)
Ca2+ and phosphoinositides: PS+R →phospholipase С activation →
hydrolysis of phosphatidylinositol 4,5-bisphosphate (phospholipids of
plasmatic membrane) into diacylglycerol and inositol 1,4,5-
trisphosphate.
23.01.2024 36
Intracellular messengers (mediators)
cGMP →stimulation of cGMP-dependent protein kinase →relaxation of smooth
muscles in vessels
23.01.2024 37
Non-receptor interactions
(non-receptor targets for PS)
Ion channels – voltage-gated channels (regulated by action potential), i.e.
open due to depolarization of cell membrane - Na+,
K+, Ca2+ and other. PSs block (more often) or activate channels.
• Slow Ca2+ channel blockers (verapamil)→inhibition of Ca2+ ion flow inside cells.
23.01.2024 38
Non-receptor interactions
(non-receptor targets for PS)
• Enzymes:
PS inhibit enzymes (cyclooxygenase→ inhibition of prostaglandin synthesis)
• Carrier systems (carrier proteins): Na+, K+- ATPase of cardiomyocyte
membranes.
• Infectious and viral pathogens;
• Toxins and venoms (reaction antidote + toxin (unithiol binds heavy metal ions;
• HCl neutralization in stomach;
• Effects of general anesthetics (PS dissolves in membrane lipids);
• Laxative effect of saline drugs (effect of hypertensive solution);
• Diuretic action of osmotic diuretics;
• Dissociation of oxidative phosphorylation (Т3, Т4);
• Inhibition of protein biosynthesis.
23.01.2024 39
Role of PS chemical structure for its action
Relationships between structure and pharmacological effects:
•-COOH, NH2-groups→molecule ionization→absorption
•Homologues orders of PS
Ammonium tetramethyl =1 un. acetyl choline, 1,4 un., 60 un., 86 un., 430 un., 58 un., 1
23.01.2024 41
Role of PS chemical structure for its action
• Prostanoic acid derivatives – PGF - ↑BP, PGЕ - ↓AD
Tubocurarine
Reason of no relationship:
•Structural formula does not reflect real conformation and properties of PS.
•Physico-chemical properties of PS when interacting with receptors is not known.
•Comparison of PS with different mode of actions: for example, Mg2+→blocks AC release from
synaptic vesicles; curare poison→blocks AC receptors: both PSs→muscle relaxation.
•Comparison of inactive PS (pro-drugs) with active metabolites.
23.01.2024 42
Influence of ambient factors on PS effects
Food – food quality, lack of food, lack of nutritional components:
Diet regime for various diseases; protein deficit→hypovitaminosis ;
Carbohydrate excess→increased rick of peptic ulcer due to aspirin intake;
Cheese, sour cream taken with antidepressant → BP↑
Temperature – affect rate of PS absorption, summer = increased tone of autonomic nervous system
→atropine intake may result in death (due to inhibited perspiration)
Isolation – excitability, aggression – psychostimulants become toxic, sedative drugs become less
effective.
Biological rhythms (daily, seasonal) – chronopharmacology (part of chronobiology) –
Investigating dependence of drug effects on time of administration. Biorhythms: circadian
(daily), hourly, weekly, monthly.
Biological rhythms characteristics: acrophase – period in a cycle during which the cycle crests or
peaks,
batiphase – the moment in cycle in which the minimum value is produced; amplitude – deviation of
function from mean; mesor – mean (e.g. mean daily) value of the function studied.
Main terms of chronopharmacology: chronopharmacokinetics – alteration of absorption,
distribution, biotransformation and excretion of PS; chronesthesia – rhythmic alteration of the body
sensitivity to PS; chronergia – rhythmic alteration of pharmacological effects of PS.
Examples: hypnotics are more effective at night, penicillins are metabolized slower during night,
ginseng is not effective in summer.
23.01.2024 43
Influence of intrinsic factors on PS effects
23.01.2024 44
Influence of intrinsic factors on PS effects
Methods of dose calculation for kids:
1. body weight; 2. body surface square; 3. depending on age:
before 1 year – 1/24, 1 year – 1/12, 2 years – 1/8, 4 years – 1/6, 6 years – ¼,
7 years – 1/3, 14 years – ½ adult dose.
4. Based on dose factor (for children with excessive body weight or lack of body
weight):
Single adult dose/kg body weight х dose factor х child body weight(kg):
Dose factor: – 0-1 year – 1,8; 1-6 years – 1,6; 6-10 years – 1,4, 10-14 year – 1,2.
There are special tables for poisons and high potent drugs.
23.01.2024 45
Influence of intrinsic factors on PS effects
23.01.2024 46
Influence of intrinsic factors on PS effects
Body weight – dose increase or decrease required (mg/kg).
Pathologic processes – alter body reaction on PS (taken to account that PS works in the
presence of pathologic process and pathologic process itself affects reaction on PS).
Exhaustion, dehydration – increased reaction on PS (1.5-2.0-fold dose decrease).
Anacid gastritis → K+ resorption decreases in 5 times compared to normal values.
↓рН → PS weak acids (phenobarbital) are deionized (become less polar) → easier transport
through biomembranes → better absorption from blood into tissues → effect strengthening.
Hence, barbiturate poisoning requires blood alkalization.
Kidney disorders → slowed excretion (in 5-10 times) → toxic effect.
Liver disorders → biotransformation defects → toxic effects.
Tuberculosis, alcoholism → гlow blood albumin level → toxic effect.
Endocrine diseases → thyroxin inhibits microsomal oxidation, myxedema (thyroid hypofunction)
→ dramatic reduction of PS effects.
PHARMACEUTICAL PHARMACOLOGICAL
(outside human body) (inside human body)
23.01.2024 50
Pharmacological drug incompatibility
with other medications
PHARMACOKINETIC PHARMACODYNAMIC
Synergism Antagonism
Absorption
Distribution
New effects
Biotransformation
Excretion
23.01.2024 51
Pharmacokinetic drug
incompatibility
at absorption from GI
1. Effect of PS on Ph value in GI
(increased рН rises degree of ionization of weak acids
and slows down their absorption)
Example of incompatibility:
Antacids and direct anticoagulant, NSAID, cardiac
glycosides, sulfanilamides, nitrofurans
23.01.2024 52
2. PS effects of GI motility
(major part of PS is absorbed in proximal part of small
intestine, thus rate of stomach content evacuation
determines time of effect commencing and its intensity)
Examples of incompatibility:
М-choline blockers and narcotic drugs decelerate evacuation and
increase toxicity of iron medications, cardiac glycosides and
NSAID
Metoclopramide accelerates GI peristalsis, and this leads to faster
effects of ethanol, acetaminophen, tetracyclines and
bensodiazepines.
But slow absorbing PS (cardiac glycosides, cimetidine, etc.) do not
have enough time for absorption and this will reduce therapeutic
efficiency.
23.01.2024 53
3. Influence of PS on membrane transport systems in
GI (enzyme activity and membrane state of intestinal
epithelium) Some PS damage cells of mucous lining
Examples on incompatibility:
Aminoglycosides, polymyxins, tetracyclines – reduce absorption of
iron, cyanocobalamin and folic acid
So, aminoglycoside intake 3-times reduces digoxin blood level.
Diphenin – slows down absorption of folic acid with consecutive
megaloblastic anemia.
23.01.2024 54
Pharmacokinetic drug
incompatibility
with other medications
at stage of distribution
_ + _ + + Drug (cation)
2 _ _
3
1 + + 4 Albumin (polyanion)
23.01.2024 56
Displacement effects is short :
Increase of drug concentration in free form affects
active sites as well as alters drug distribution and
elimination.
С’
23.01.2024 57
Long increase of concentration (and clinical
signs) are possible:
• If key sites of distribution and elimination
are saturated.
• if therapeutic index of the drug being
displaced is low
С’
t
23.01.2024 58
Drug incompatibility
with other medications
23.01.2024 59
Drug incompatibility
with other medications
biotransformation
I phase II phase
Metabolism Conjugation
(lowered pharmacological (increased hydrophilicity
activity – water solubility
23.01.2024 61
Drug incompatibility
with other medications
conjugation
Elimination
Major part of NSAID (in particular indomethacin)
reduce (via COX-1 suppression):
• rate of glomerular filtration,
• velocity of urine formation,
• free water clearance,
• electrolyte excretion.
and disturb elimination pharmaceutical substances, that
are excreted through kidneys
23.01.2024 63
Combination PS effects
23.01.2024 64
Combination PS effects
2. Antagonism – interaction between PS resulting in reduced
or disappeared effects of one or both PSs.
Types:
а) pharmaceutical – occurs at different stages of production, storage or administration of
PS (in one syringe) with formation of inactive or toxic compounds, impaired solubility
(sedimentation), stratification of emulsions, melting of powders (eutectic mixtures).
б) physical – physical interaction of PSs (adsorption on activated carbons);
в) chemical – chemical interaction with formation of inactive complexes (cuprenil and
copper medications);
г) functional (pharmacological):
direct – PSs affect the same receptors (acetyl choline and blocker of acetyl choline
receptors);
indirect – PSs affect different receptors (or functional elements) (acetyl choline →
binding to acetyl choline receptors → bronchospasm; adrenaline → binding to
noradrenaline receptors → bronchial dilatation);
can be unilateral (strychnine and ether – antagonists; ether reduce strychnine effects
(convulsions), but strychnine does not reduce ether effects).
23.01.2024 65
Pharmacodynamic drug
interaction
5
3
Synergism:
2 1- sub-additive effect
2- summation
q 3-potentiation
4 4- ANTAGONISM
5- Synergy-antagosnism
23.01.2024 66
Drug interaction
Practical meaning:
23.01.2024 67
Body reactions on repeated drug intake
1. Effect weakening (habituation, tolerance – latin. tolerantia – capacity to stand to, patience)
– increase of body sustainability to drug associated with reduced therapeutic activity (toxic
effects). This may be due to:
• Limited absorption (inflammation, mucous lining GI, scars);
• Induction of microsomal oxidizing;
• Receptor desensitization. Developing in several days to several months.
Tachyphylaxis – rapidly diminishing response to successive doses of a drug, rendering it less
effective in several minutes and up to days.
Mithridatism – gradually developing habituation to medications and poisons occurring due to
long intake of increasing doses from very small to the large ones.
2. Effect enhancing – accumulation – increase of drug amount in the body and its effects:
• Material cumulation amounts of PS getting into body is higher than eliminated; may be
necessary for therapeutic effect (cardiac glycosides), may be caused by liver or kidney
disorders → toxic effects.
• Functional cumulation – enhanced effects of PS administered repeatedly without increase
of its blood or tissue concentration.
23.01.2024 68
Drug addiction
predilection– aim of taking medication is not corresponding with its indication
base – need in mood alteration, pleasant relaxation,, facilitation, increase of working capacity,, an
effort to relieve pain, the desire for intoxication and easy ecstasy.
Predilection leads to addiction – condition associated with forced desire to take a medication
(or chemical compound) for a long period or periodically for experience of psychic effect again
or to avoid worsening of general state due to the lack of medication (cancellation).
Primary reason is a property of such medication and other compounds to induce pleasant and/or
unusual feeling leading to psychological dependence.
May medications and chemical compounds induce formation of physical dependence, i.e.
condition which is characterized by severe disturbance of somatic status when intake of he drug
or compound is discontinued. This condition is termed withdrawal syndrome.
Intake of medication or chemical compounds makes relief of the general conditions and continuing
intake reduce withdrawal syndrome.
23.01.2024 69
Drug addition
Narcotic compound (narcotic) – first of all, this is first of all, a legal term
indicating that some authority organization (in Russia – Russian ministry of
health) refers this compound and narcotic and included it into the official list of
narcotic compounds.
23.01.2024 70
Drug side effects
23.01.2024 71
Drug side effects
23.01.2024 72
Drug influence of fetus and newborn
23.01.2024 73
23.01.2024 74
EL FINAL
23.01.2024 75